• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用顺铂碘化油乳剂和明胶海绵经导管动脉化疗栓塞术治疗不可切除的肝细胞癌。

Treatment of inoperable hepatocellular carcinoma by transcatheter arterial chemoembolization using an emulsion of cisplatin in iodized oil and gelfoam.

作者信息

Ngan H, Lai C L, Fan S T, Lai E C, Yuen W K, Tso W K

机构信息

Department of Diagnostic Radiology, University of Hong Kong.

出版信息

Clin Radiol. 1993 May;47(5):315-20. doi: 10.1016/s0009-9260(05)81446-1.

DOI:10.1016/s0009-9260(05)81446-1
PMID:8389682
Abstract

Eighty patients with inoperable hepatocellular carcinoma (HCC) were treated by transcatheter arterial chemoembolization using an emulsion of Lipiodol and Cisplatin. In 59 patients, gelfoam embolization was also given. The tumour size ranged from 0.5 cm to 33 cm in maximum diameter with the median diameter being 8 cm. The chemoembolization sessions were repeated every 1 1/2 to 3 months. The number of sessions the patients underwent varied from 1 to 11, with the mean number of sessions being 3.7. The HCC either disappeared completely or decreased in size in 44 patients (55%). In patients having an HCC of 12 cm or less in size, 31 out of 41 (75.6%) who had the addition of gelfoam demonstrated decrease in tumour size, while seven out of 11 (63.6%) without the addition of gelfoam demonstrated decrease in tumour size. In patients having an HCC of more than 12 cm in size, only six out of 18 (33.3%) who had the addition of gelfoam demonstrated reduction in tumour size and none of the 10 patients without the addition of gelfoam responded. Thus, HCCs of 12 cm or less in size responded better than larger ones to chemoembolization (P < 0.0001) while the addition of gelfoam enhanced the response (P = 0.039). The 1 year survival rate for the 80 patients was 53% and the 2 years survival rate was 38%. The median survival was 13 months. For patients having an HCC of 12 cm or less in size, the 1 year and 2 year survival rates were 69% and 47% respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

80例无法手术切除的肝细胞癌(HCC)患者接受了使用碘油和顺铂乳剂的经导管动脉化疗栓塞治疗。59例患者还进行了明胶海绵栓塞。肿瘤最大直径范围为0.5厘米至33厘米,中位直径为8厘米。化疗栓塞疗程每1.5至3个月重复一次。患者接受的疗程数从1次到11次不等,平均疗程数为3.7次。44例患者(55%)的HCC完全消失或缩小。在HCC大小为12厘米或更小的患者中,41例接受明胶海绵栓塞的患者中有31例(75.6%)肿瘤缩小,而11例未接受明胶海绵栓塞的患者中有7例(63.6%)肿瘤缩小。在HCC大小超过12厘米的患者中,18例接受明胶海绵栓塞的患者中只有6例(33.3%)肿瘤缩小,10例未接受明胶海绵栓塞的患者均无反应。因此,大小为12厘米或更小的HCC对化疗栓塞的反应比更大的肿瘤更好(P<0.0001),而添加明胶海绵可增强反应(P = 0.039)。80例患者的1年生存率为53%,2年生存率为38%。中位生存期为13个月。对于HCC大小为12厘米或更小的患者,1年和2年生存率分别为69%和47%。(摘要截短至250字)

相似文献

1
Treatment of inoperable hepatocellular carcinoma by transcatheter arterial chemoembolization using an emulsion of cisplatin in iodized oil and gelfoam.使用顺铂碘化油乳剂和明胶海绵经导管动脉化疗栓塞术治疗不可切除的肝细胞癌。
Clin Radiol. 1993 May;47(5):315-20. doi: 10.1016/s0009-9260(05)81446-1.
2
Transcatheter arterial chemoembolization in inoperable hepatocellular carcinoma: four-year follow-up.不可切除肝细胞癌的经动脉化疗栓塞术:四年随访
J Vasc Interv Radiol. 1996 May-Jun;7(3):419-25. doi: 10.1016/s1051-0443(96)72881-6.
3
A pre-operative chemoembolization therapy using lipiodol, cisplatin and gelatin sponge for hepatocellular carcinoma.
Cancer Chemother Pharmacol. 1989;23 Suppl:S126-8. doi: 10.1007/BF00647258.
4
Chemoembolization with cisplatin, lipiodol and Gelfoam and subsequent systemic chemotherapy with cisplatin and interferon in patients with hepatocellular carcinoma: a non-randomized prospective study.顺铂、碘油和明胶海绵化疗栓塞联合顺铂和干扰素序贯全身化疗治疗肝细胞癌患者:一项非随机前瞻性研究
Int J Oncol. 2003 Sep;23(3):811-9.
5
Segmental transcatheter arterial chemoembolization treatment in patients with cirrhosis and inoperable hepatocellular carcinomas.肝硬化合并不可切除肝细胞癌患者的节段性经导管动脉化疗栓塞治疗
J Vasc Interv Radiol. 2002 Oct;13(10):995-9. doi: 10.1016/s1051-0443(07)61863-6.
6
Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion.经导管动脉化疗栓塞术治疗不可切除肝细胞癌患者的长期预后:顺铂碘油混悬液与盐酸多柔比星乳剂的比较
J Vasc Interv Radiol. 2001 Jul;12(7):847-54. doi: 10.1016/s1051-0443(07)61510-3.
7
Long-term outcomes of transcatheter arterial chemoembolization with autologous blood clot for unresectable hepatocellular carcinoma.经导管动脉化疗栓塞联合自体血凝块治疗不可切除肝细胞癌的长期疗效
Int J Oncol. 2002 Aug;21(2):427-32.
8
Chemoembolization in liver malignant involvement. Experiences on 17 cases.肝恶性受累的化疗栓塞术。17例经验。
Minerva Chir. 1994 Apr;49(4):281-5.
9
[-Comparison of lipiodol-assisted chemoembolization versus only conservative therapy in patients with nonresectable hepatocellular carcinomas-].[碘油辅助化疗栓塞术与单纯保守治疗不可切除肝细胞癌患者的比较]
Z Gastroenterol. 1996 Mar;34(3):205-6.
10
Symptom relief and survival after chemo-embolization with adriamycin, lipiodol and gelfoam for hepatocellular carcinoma.阿霉素、碘油和明胶海绵化疗栓塞治疗肝细胞癌后的症状缓解与生存情况
Australas Radiol. 1993 May;37(2):173-6. doi: 10.1111/j.1440-1673.1993.tb00044.x.

引用本文的文献

1
Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016.门静脉癌栓型肝细胞癌的管理:2016年回顾与更新
World J Gastroenterol. 2016 Aug 28;22(32):7289-300. doi: 10.3748/wjg.v22.i32.7289.
2
Evaluating tumors in transcatheter arterial chemoembolization (TACE) using dual-phase cone-beam CT.使用双期锥形束CT评估经动脉化疗栓塞术(TACE)中的肿瘤。
Minim Invasive Ther Allied Technol. 2011 Sep;20(5):276-81. doi: 10.3109/13645706.2010.536243. Epub 2010 Nov 17.
3
Computed tomography perfusion in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma.
计算机断层扫描灌注成像在评估经动脉化疗栓塞治疗肝细胞癌疗效中的应用
World J Gastroenterol. 2008 Oct 7;14(37):5738-43. doi: 10.3748/wjg.14.5738.
4
Outcome of transarterial chemoembolization in patients with inoperable hepatocellular carcinoma eligible for radiofrequency ablation.适用于射频消融的不可切除肝细胞癌患者经动脉化疗栓塞的疗效
World J Gastroenterol. 2005 Aug 7;11(29):4465-71. doi: 10.3748/wjg.v11.i29.4465.
5
Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective.肝细胞癌的局部区域治疗:外科医生视角的批判性综述
Ann Surg. 2002 Apr;235(4):466-86. doi: 10.1097/00000658-200204000-00004.
6
Unresectable hepatocellular carcinoma in cirrhosis: survival, prognostic factors, and unexpected side effects after transcatheter arterial chemoembolization.肝硬化中不可切除的肝细胞癌:经动脉化疗栓塞后的生存情况、预后因素及意外副作用
Dig Dis Sci. 1996 Dec;41(12):2332-9. doi: 10.1007/BF02100123.
7
Chemoembolisation with lipiodol and doxorubicin: applicability in British patients with hepatocellular carcinoma.碘油与阿霉素化疗栓塞术:在英国肝细胞癌患者中的适用性
Gut. 1996 Jan;38(1):125-8. doi: 10.1136/gut.38.1.125.